China Resources Medical Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
China Resources Medical Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 31.9% bzw. 5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 35.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12% betragen.
Wichtige Informationen
31.9%
Wachstumsrate der Gewinne
35.2%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 18.5% |
| Wachstumsrate der Einnahmen | 5.0% |
| Zukünftige Eigenkapitalrendite | 12.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 04 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Returns At China Resources Medical Holdings (HKG:1515) Appear To Be Weighed Down
Nov 14
Market Participants Recognise China Resources Medical Holdings Company Limited's (HKG:1515) Earnings Pushing Shares 34% Higher
Oct 02We Think You Can Look Beyond China Resources Medical Holdings' (HKG:1515) Lackluster Earnings
May 06China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet
Apr 26Shareholders Should Be Pleased With China Resources Medical Holdings Company Limited's (HKG:1515) Price
Mar 09Is China Resources Medical Holdings (HKG:1515) Using Too Much Debt?
Nov 29China Resources Medical Holdings' (HKG:1515) Returns Have Hit A Wall
Oct 19Analyst Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher
Aug 30Should You Think About Buying China Resources Medical Holdings Company Limited (HKG:1515) Now?
Aug 26China Resources Medical Holdings (HKG:1515) Has A Pretty Healthy Balance Sheet
Jun 30China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around
May 12Analysts Just Published A Bright New Outlook For China Resources Medical Holdings Company Limited's (HKG:1515)
Apr 03Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?
Feb 21China Resources Medical Holdings (HKG:1515) May Have Issues Allocating Its Capital
Jan 10We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease
Nov 30Is China Resources Medical Holdings Company Limited (HKG:1515) Trading At A 23% Discount?
Oct 18China Resources Medical Holdings (HKG:1515) Will Want To Turn Around Its Return Trends
Sep 21Are Investors Undervaluing China Resources Medical Holdings Company Limited (HKG:1515) By 47%?
Jul 13Is It Time To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?
Jun 24China Resources Medical Holdings (HKG:1515) Is Increasing Its Dividend To HK$0.12
Jun 03China Resources Medical Holdings (HKG:1515) Will Pay A Larger Dividend Than Last Year At HK$0.12
Apr 27We Think China Resources Medical Holdings (HKG:1515) Can Manage Its Debt With Ease
Apr 22Growth Investors: Industry Analysts Just Upgraded Their China Resources Medical Holdings Company Limited (HKG:1515) Revenue Forecasts By 45%
Mar 30Is Now An Opportune Moment To Examine China Resources Medical Holdings Company Limited (HKG:1515)?
Jan 27China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 37% Below Their Intrinsic Value Estimate
Jan 03China Resources Medical Holdings (HKG:1515) Will Be Hoping To Turn Its Returns On Capital Around
Nov 19Is It Too Late To Consider Buying China Resources Medical Holdings Company Limited (HKG:1515)?
Oct 26An Intrinsic Calculation For China Resources Medical Holdings Company Limited (HKG:1515) Suggests It's 44% Undervalued
Sep 20Here's Why China Resources Medical Holdings (HKG:1515) Can Manage Its Debt Responsibly
Sep 06China Resources Medical Holdings (HKG:1515) Might Be Having Difficulty Using Its Capital Effectively
Aug 17Broker Revenue Forecasts For China Resources Medical Holdings Company Limited (HKG:1515) Are Surging Higher
Jun 21China Resources Medical Holdings Company Limited (HKG:1515) Shares Could Be 34% Below Their Intrinsic Value Estimate
Jun 09Investors Can Find Comfort In China Resources Medical Holdings' (HKG:1515) Earnings Quality
May 03China Resources Medical Holdings Company Limited (HKG:1515) Is Yielding 1.4% - But Is It A Buy?
Apr 22We Think China Resources Medical Holdings (HKG:1515) Can Stay On Top Of Its Debt
Mar 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 11,341 | 886 | N/A | 1,387 | 4 |
| 12/31/2025 | 10,908 | 792 | 1,213 | 1,511 | 6 |
| 12/31/2024 | 10,421 | 711 | 984 | 1,235 | 6 |
| 6/30/2024 | 9,970 | 294 | 621 | 1,162 | N/A |
| 3/31/2024 | 10,039 | 276 | 665 | 1,179 | N/A |
| 12/31/2023 | 10,108 | 258 | 708 | 1,195 | N/A |
| 9/30/2023 | 9,958 | 338 | 732 | 1,251 | N/A |
| 6/30/2023 | 9,809 | 419 | 756 | 1,307 | N/A |
| 3/31/2023 | 8,855 | 342 | 577 | 1,086 | N/A |
| 12/31/2022 | 7,901 | 266 | 397 | 864 | N/A |
| 9/30/2022 | 6,891 | 365 | 422 | 772 | N/A |
| 6/30/2022 | 5,881 | 463 | 447 | 680 | N/A |
| 3/31/2022 | 5,164 | 441 | 479 | 695 | N/A |
| 12/31/2021 | 4,447 | 418 | 512 | 710 | N/A |
| 9/30/2021 | 4,031 | 410 | 392 | 628 | N/A |
| 6/30/2021 | 3,615 | 402 | 271 | 546 | N/A |
| 3/31/2021 | 3,183 | 356 | 349 | 595 | N/A |
| 12/31/2020 | 2,751 | 310 | 426 | 644 | N/A |
| 9/30/2020 | 2,404 | 313 | 483 | 614 | N/A |
| 6/30/2020 | 2,058 | 315 | 540 | 584 | N/A |
| 3/31/2020 | 2,087 | 353 | 435 | 475 | N/A |
| 12/31/2019 | 2,115 | 391 | 330 | 366 | N/A |
| 9/30/2019 | 2,112 | 401 | 263 | 300 | N/A |
| 6/30/2019 | 2,108 | 412 | 196 | 234 | N/A |
| 3/31/2019 | 2,084 | 421 | 236 | 284 | N/A |
| 12/31/2018 | 2,059 | 431 | 277 | 334 | N/A |
| 9/30/2018 | 1,996 | 364 | 317 | 371 | N/A |
| 6/30/2018 | 1,932 | 298 | 357 | 407 | N/A |
| 3/31/2018 | 1,905 | 360 | N/A | 433 | N/A |
| 12/31/2017 | 1,878 | 421 | N/A | 460 | N/A |
| 9/30/2017 | 1,784 | -446 | N/A | 377 | N/A |
| 6/30/2017 | 1,690 | -1,312 | N/A | 294 | N/A |
| 3/31/2017 | 1,611 | -1,410 | N/A | 259 | N/A |
| 12/31/2016 | 1,533 | -1,507 | N/A | 224 | N/A |
| 9/30/2016 | 1,504 | -656 | N/A | 227 | N/A |
| 6/30/2016 | 1,475 | 196 | N/A | 230 | N/A |
| 3/31/2016 | 1,424 | 181 | N/A | 231 | N/A |
| 12/31/2015 | 1,372 | 167 | N/A | 232 | N/A |
| 9/30/2015 | 1,337 | 208 | N/A | 246 | N/A |
| 6/30/2015 | 1,302 | 249 | N/A | 261 | N/A |
| 3/31/2015 | 1,254 | 240 | N/A | 268 | N/A |
| 12/31/2014 | 1,206 | 230 | N/A | 274 | N/A |
| 9/30/2014 | 1,090 | 176 | N/A | 238 | N/A |
| 6/30/2014 | 975 | 122 | N/A | 202 | N/A |
| 3/31/2014 | 931 | 106 | N/A | 186 | N/A |
| 12/31/2013 | 887 | 90 | N/A | 170 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1515Das prognostizierte Gewinnwachstum (31.9% pro Jahr) liegt über der Sparquote (2.3%).
Ertrag vs. Markt: 1515Die Erträge des Unternehmens (31.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (11.6% pro Jahr).
Hohe Wachstumserträge: 1515Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 1515Die Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (7.8% pro Jahr).
Hohe Wachstumseinnahmen: 1515Die Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1515Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12%).